- Home
- STR vs AKRO Comparison
STR vs AKRO Comparison
Compare STR & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STR
- AKRO
- Stock Information
- Founded
- STR 2016
- AKRO 2017
- Country
- STR United States
- AKRO United States
- Employees
- STR N/A
- AKRO N/A
- Industry
- STR Oil & Gas Production
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- STR Energy
- AKRO Health Care
- Exchange
- STR Nasdaq
- AKRO Nasdaq
- Market Cap
- STR 1.4B
- AKRO 3.9B
- IPO Year
- STR N/A
- AKRO 2019
- Fundamental
- Price
- STR $18.61
- AKRO $51.69
- Analyst Decision
- STR Buy
- AKRO Strong Buy
- Analyst Count
- STR 6
- AKRO 6
- Target Price
- STR $25.60
- AKRO $82.50
- AVG Volume (30 Days)
- STR 1.4M
- AKRO 1.6M
- Earning Date
- STR 08-06-2025
- AKRO 08-08-2025
- Dividend Yield
- STR 7.53%
- AKRO N/A
- EPS Growth
- STR N/A
- AKRO N/A
- EPS
- STR 0.52
- AKRO N/A
- Revenue
- STR $636,538,000.00
- AKRO N/A
- Revenue This Year
- STR N/A
- AKRO N/A
- Revenue Next Year
- STR N/A
- AKRO N/A
- P/E Ratio
- STR $35.71
- AKRO N/A
- Revenue Growth
- STR 7.18
- AKRO N/A
- 52 Week Low
- STR $14.58
- AKRO $21.34
- 52 Week High
- STR $25.64
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- STR 50.57
- AKRO 45.35
- Support Level
- STR $17.60
- AKRO $50.13
- Resistance Level
- STR $18.37
- AKRO $53.60
- Average True Range (ATR)
- STR 0.57
- AKRO 2.03
- MACD
- STR -0.11
- AKRO -0.83
- Stochastic Oscillator
- STR 47.53
- AKRO 6.37
About STR Sitio Royalties Corp.
Sitio Royalties Corp is a pure-play mineral and royalty company. The group focuses on investing in mineral and royalty interests in the Permian and other productive U.S. oil basins.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.